Targeting Telomerase as a Therapeutic Strategy for Difficult-to-Treat Melanoma
PHILADELPHIA — (April 25, 2018) — Targeting telomerase was effective at killing NRAS-mutant melanoma cells, and the impact was further enhanced when the strategy was paired with an inhibitor of mitochondrial function, according to study results by The Wistar Institute published in Oncogene.
“Many melanoma patients do not benefit from new treatment options or experience disease progression because of resistance. Our research advances the search for novel therapeutic strategies to treat NRAS-mutant melanoma, which is highly resistant to most therapies and associated with poor prognosis,” said lead researcher Jessie Villanueva, Ph.D., assistant professor in the Molecular & Cellular Oncogenesis Program at Wistar.
Targeting NRAS as well as the other oncogenes of the Ras family has proven extremely challenging, according to Villanueva, and researchers have resorted to searching for vulnerabilities in NRAS-mutant cancer cells that can provide alternative therapeutic targets.
Mutations in the regulatory element of the TERT gene, which encodes the catalytic subunit of telomerase, are found in more than 70 percent of melanomas. Telomerase is an enzyme that protects the integrity of chromosome ends during replication and represents a promising target for cancer therapy because it is absent in most normal adult cells while its reactivation in malignant cells allows continuous cell divisions.
“We linked the presence of mutant NRAS to TERT expression and showed that NRAS mutant melanoma cells are highly dependent on telomerase,” said Villanueva. “We also demonstrated the therapeutic value of exploiting this dependency by inducing telomere dysfunction, which caused cell death selectively in NRAS mutant cells and not in normal cells that do not express telomerase.”
Villanueva and colleagues studied the consequence of NRAS depletion on gene expression in NRAS-mutant melanoma cells, focusing on genes that regulate proliferation. They observed a strong decrease in expression of TERT. They then inhibited telomerase activity via TERT gene silencing or induced telomere dysfunction through a telomerase substrate, called 6-thio-dG; both interventions led to extensive cell death and DNA damage. They also observed an increase in expression of several enzymes involved in the function of mitochondria, the organelles designated to energy production, suggesting that following telomere dysfunction cells put in place an adaptive metabolic response that helps them cope with the damage.
“We asked whether inhibition of mitochondrial function could synergize with the anti-melanoma effects of telomere dysfunction,” said Patricia Reyes-Uribe, a research assistant in the Villanueva Lab and the first author of the study. “We found that the mitochondrial inhibitor gamitrinib enhances the cytotoxic effects of TERT depletion or 6-thio-dG selectively in NRAS mutant tumor cells.”
These observations were reproduced in vivo in a mouse model of NRAS-mutant melanoma by showing that the combination of gamitrinib and 6-thio-dG reduced tumor size and substantially prolonged survival.
“Our work provides proof-of-principle that we can successfully address drug resistance by developing combination therapies that simultaneously impair telomerase and block adaptive resistance mechanisms,” added Villanueva.
This work was supported by National Institutes of Health grants R01CA215733, K01CA175269, P01CA114046, and P50CA174523 and by grants from the American Cancer Society, the V Foundation for Cancer Research, the Melanoma Research Alliance, the Melanoma Research Foundation, and the Martha Rogers Trust. This project was funded, in part, under a grant from the Pennsylvania Department of Health. Core support for The Wistar Institute was provided by the Cancer Center Support Grant P30 CA010815.
Co-authors of this study from The Wistar Institute include Maria Paz Adrianzen-Ruesta, Zhong Deng, Ileabett Echevarria-Vargas, Steven Saheb, Qin Liu, Dario C. Altieri, Maureen E. Murphy, and Paul M. Lieberman. Other co-authors include Ilgen Mender and Jerry W. Shay from the University of Texas Southwestern Medical Center.
The Wistar Institute is an international leader in biomedical research with special expertise in cancer research and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the United States, Wistar has held the prestigious Cancer Center designation from the National Cancer Institute since 1972. The Institute works actively to ensure that research advances move from the laboratory to the clinic as quickly as possible. wistar.org.